Vincristine neurotoxicity in Charcot-Marie-Tooth syndrome.

Abstract	The case of a patient with Charcot-Marie-Tooth syndrome and diffuse large-cell lymphoma, in whom a severe generalized weakness developed after the intravenous administration of vincristine (2 mg) during combination chemotherapy, is reported. Spontaneous resolution of the severe weakness occurred when teniposide was substituted for vincristine in the chemotherapy regimen.
Authors	J D Griffiths, R J Stark, J C Ding, I A Cooper
Journal	The Medical journal of Australia (Med J Aust) Vol. 143 Issue 7 Pg. 305-6 (Sep 30 1985) ISSN: 0025-729X [Print] Australia
PMID	4046919 (Publication Type: Case Reports, Journal Article)
Chemical References	Vincristine Cyclophosphamide Prednisolone
Topics	Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Charcot-Marie-Tooth Disease (complications, drug therapy) Cyclophosphamide (administration & dosage) Female Humans Lymphoma (complications, drug therapy) Middle Aged Muscular Atrophy (complications) Neuromuscular Diseases (chemically induced, pathology) Prednisolone (administration & dosage) Vincristine (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!